VivoSeq
Other

PD-1 Inhibitor

0

Pipeline Programs↗

13

Active Trials↗

2

Companies Involved↗

PD-1 Inhibitor is an early-stage landscape with 0 programs across 2 companies. The most active players are Coordination Pharmaceuticals, Inc., Phanes Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Coordination Pharmaceuticals, Inc.

0 programs

PreclinicalP

Phanes Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Recruiting9 · 38%
Unknown status8 · 33%
Active, not recruiting3 · 13%
Completed3 · 13%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

24 trials

PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Recruiting·—·Phase 2·NCT06186609·68 enrolled
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT06505486·21 enrolled
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
Recruiting·WWest China Hospital·Phase 3·NCT06627712·318 enrolled
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
Recruiting·RRuijin Hospital·Phase 2·NCT07198165·104 enrolled
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Recruiting·FFudan University·Phase 2·NCT06455124·60 enrolled
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Recruiting·SSun Yat-sen University·N/A·NCT06622031·42 enrolled
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT05772273·43 enrolled
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Recruiting·CCoordination Pharmaceuticals, Inc.·Phase 1/2·NCT05838729·16 enrolled
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Recruiting·PPhanes Therapeutics·Phase 1/2·NCT05431270·40 enrolled
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
Active, not recruiting·RRenJi Hospital·N/A·NCT06762158·50 enrolled
CD40 Agonist and PD-1 Inhibitor in HNSCC
Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT06159621·27 enrolled
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Active, not recruiting·TTang-Du Hospital·Phase 2·NCT05400070·45 enrolled
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07432568·30 enrolled
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03463876·190 enrolled
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03945604·32 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)